Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
The development of anti-HER2 agents has been one of the most meaningful advancements in the management of metastatic breast cancer, significantly improving survival outcomes. Despite the efficacy of anti-HER2 monoclonal antibodies, concurrent chemotherapy is still needed to maximize response. Antibo...
| Publicado en: | Breast Cancer Research Vol. 23; no. 1; pp. 1 - 12 |
|---|---|
| Autores principales: | , , |
| Formato: | research review Journal Article |
| Publicado: |
BioMed Central
8/11/2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=151860815&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 151860815 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14655411 8UYJ jtl: Breast Cancer Research issn: 14655411 maglogo: N pubinfo: dt: 8/11/2021 vid: 23 iid: 1 pid: 24147 pub: BioMed Central artinfo: ui: 151860815 151860815 NLM34380530 151860815 10.1186/s13058-021-01459-y NLM34380530 151860815 ppf: 1 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. aug: au: Ferraro, Emanuela Drago, Joshua Z. Modi, Shanu affil: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA sug: subj: Breast Neoplasms Drug Therapy Antineoplastic Agents Therapeutic Use Receptors, Cell Surface Metabolism Antibodies Therapeutic Use Antibodies Pharmacodynamics Central Nervous System Neoplasms Drug Therapy Human Antibodies Adverse Effects Breast Neoplasms Metabolism Antineoplastic Agents Adverse Effects Antineoplastic Agents Pharmacodynamics Central Nervous System Neoplasms Female Breast Neoplasms Pathology Adverse Drug Event Receptors, Cell Surface Antagonists and Inhibitors Comparative Studies Multicenter Studies Evaluation Research Validation Studies Clinical Assessment Tools Scales Female ab: The development of anti-HER2 agents has been one of the most meaningful advancements in the management of metastatic breast cancer, significantly improving survival outcomes. Despite the efficacy of anti-HER2 monoclonal antibodies, concurrent chemotherapy is still needed to maximize response. Antibody-drug conjugates (ADCs) are a class of therapeutics that combines an antigen-specific antibody backbone with a potent cytotoxic payload, resulting in an improved therapeutic index. Two anti-HER2 ADCs have been approved by the FDA with different indications in HER2-positive breast cancer. Ado-trastuzumab emtansine (T-DM1) was the first-in-class HER2-targeting ADC, initially approved in 2013 for metastatic patients who previously received trastuzumab and a taxane, and the label was expanded in 2019 to include adjuvant treatment of high-risk patients with residual disease after neoadjuvant taxane and trastuzumab-based therapy. In 2020, trastuzumab deruxtecan (T-DXd) was the second approved ADC for patients who had received at least 2 lines of anti-HER2-based therapy in the metastatic setting. The success of these two agents has transformed the treatment of HER2-positive breast cancer and has re-energized the field of ADC development. Given their advanced pharmaceutical properties, next-generation HER2-targeted ADCs have the potential to be active beyond traditional HER2-positive breast cancer and may be effective in cells with low expression of HER2 or ERBB2 mutations, opening a spectrum of new possible clinical applications. Ongoing challenges include improving target-specificity, optimizing the toxicity profile, and identifying biomarkers for patient selection. The aim of this review is to summarize the principal molecular, clinical, and safety characteristics of approved and experimental anti-HER2 ADCs, contextualizing the current and future landscape of drug development. pubtype: Academic Journal doctype: research review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|